摘要
目的比较培美曲塞、顺铂及吉西他滨术前新辅助化疗与常规术式对肺腺癌患者肺功能指标及1~3年生存状况的影响。方法选取2016年1月至2017年9月在朝阳市第二医院接受治疗的肺腺癌患者114例作为研究对象,按随机数字表法分为观察组与对照组,各57例。两组患者常规给予肺癌根治术治疗,观察组在术前42d接受培美曲塞、顺铂及吉西他滨的综合新辅助化疗,随访3年,比较两组疗效、肺功能指标及1~3年生存状况。结果观察组治疗有效率为70.18%,明显高于对照组的50.88%(P<0.05)。治疗后两组第一秒钟用力呼气容积(FEV1)较治疗前升高,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组1、2、3年生存率分别为94.74%、87.72%、78.95%,较对照组的82.46%、71.93%、61.40%明显更高(P<0.05)。结论培美曲塞、顺铂及吉西他滨实施术前新辅助化疗对肺腺癌患者的疗效较好,能够有效改善其肺功能指标,且患者的1~3年生存率也相对较高。
Objective To compare the effects of neoadjuvant chemotherapy and routine surgery before pemetrexed, cisplatin and gemcitabine on lung function indexes and 1-3 year survival status of patients with lung adenocarcinoma. Methods A total of 114 patients with lung adenocarcinoma admitted to Chaoyang Second Hospital from January 2016 to September 2017 were selected as the research objects. According to the random number table, they were divided into an observation group and a control group, with 57 cases in each group. Both groups were routinely treated with radical resection of lung cancer, and neoadjuvant chemotherapy of pemetrexed, cisplatin and gemcitabine were given to the observation group 42 d before operation. Followed up for three years, their efficacy, lung function index and survival status were compared. Results The total effective rate of the observation group was 70.18%, significantly higher than the control group of 50.88%(P<0.05). After treatment, the FEV1 of the 2 groups was significantly higher than that before treatment, and the observation group was higher than the control group(P<0.05). The 1-3 year survival rates in the observation group were 94.74%, 87.72% and 78.95%, which were significantly higher, compared with the control group of 82.46%, 71.93% and 61.40%.(P<0.05). Conclusion Preoperative neoadjuvant chemotherapy with pemetrexed,cisplatin and gemcitabine is effective in lung adenocarcinoma patients, can effectively improve its lung function indicators, and the 1-3-year survival rate is relatively high.
作者
赵旭
ZHAO Xu(Department of Thoracic Surgery,Chaoyang Second Hospital,Chaoyang 122099,China)
出处
《中国药物经济学》
2021年第12期37-40,共4页
China Journal of Pharmaceutical Economics
关键词
培美曲塞
顺铂
吉西他滨
术前新辅助化疗
常规术式
肺腺癌
肺功能指标
生存状况
Pemetrexed
Cisplatin
Gemcitabine
Preoperative neoadjuvant chemotherapy
Routine procedure
Lung adenocarcinoma
Lung function index
Survival status
